Merrill keeps Human Genome at buy

Human Genome Sciences, Inc. was maintained by Merrill Lynch analyst Hari Sambasivam at a buy ahead of the company's third-quarter results. The analyst's estimates for the quarter include total revenues of $4.7 million, total expenses of $64 million (including research and development of $50.0 million) and a pro forma net loss of $59.6 million, or $0.45 per share. Sambasivam will be looking for updates on the start of enrollment in the Albuferon phase 3 trials as well as evidence of a reduced cash burn rate. Shares of the Rockville, Md.-based biopharmaceutical company were up 13 cents, or 0.95%, at $13.83. (Nasdaq: HGSI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.